What is the recommended SMART (Single Maintenance And Reliever Therapy) regimen using budesonide‑formoterol for an adult with persistent asthma inadequately controlled on short‑acting β‑agonist alone, including initial dosing and step‑up options?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

SMART Asthma Therapy: Budesonide-Formoterol Maintenance and Reliever Regimen

For adults with moderate to severe persistent asthma inadequately controlled on SABA alone, initiate budesonide-formoterol 160/4.5 mcg two inhalations twice daily as maintenance, plus additional inhalations as needed for symptom relief (maximum 12 total inhalations per day). 1

Initial Dosing Strategy

The starting dose depends on asthma severity at baseline:

  • Moderate to severe persistent asthma (most patients inadequately controlled on SABA alone): Start with budesonide-formoterol 160/4.5 mcg, 2 inhalations twice daily (morning and evening, 12 hours apart) 2
  • Mild persistent asthma: May consider budesonide-formoterol 80/4.5 mcg, 2 inhalations twice daily 2

The 2020 NAEPP guidelines provide a strong recommendation with high certainty of evidence for ICS-formoterol as both maintenance and reliever therapy in patients aged 4 years and older with moderate to severe persistent asthma, specifically comparing it favorably to higher-dose ICS alone with SABA or same-dose ICS-LABA with SABA 1. This is the highest quality guideline evidence available.

Reliever Dosing

Critical implementation detail: Patients take one additional inhalation of the same budesonide-formoterol inhaler whenever symptoms occur, up to a maximum of 12 total inhalations in any 24-hour period for adults and adolescents ≥12 years 2, 3. This delivers up to 54 mcg of formoterol daily, which is within safe limits 3.

Eliminate all SABA inhalers - patients should not use additional short-acting beta-agonists or any other LABA products while on SMART therapy 2.

Step-Up Options

If asthma remains inadequately controlled after 1-2 weeks on budesonide-formoterol 80/4.5 mcg:

  1. Step up to budesonide-formoterol 160/4.5 mcg, 2 inhalations twice daily plus as-needed 2
  2. Maximum dose: 160/4.5 mcg, 2 inhalations twice daily (maintenance) plus as-needed inhalations up to 12 total daily 2

If control fails on maximum SMART dosing, re-evaluate and consider:

  • Adding additional ICS dose
  • Adding LAMA (long-acting muscarinic antagonist) to the regimen 1
  • Initiating oral corticosteroids for severe cases 2

Evidence Strength and Clinical Context

The SMART regimen demonstrates 44% reduction in risk of first severe exacerbation (HR 0.56,95% CI 0.32-0.95) and 38% reduction in overall exacerbation rates compared to fixed-dose ICS-LABA plus SABA 4. A 2022 meta-analysis of 4,863 patients confirmed 30% reduced risk of severe exacerbations (HR 0.70,95% CI 0.58-0.85) when switching poorly controlled patients to SMART versus continuing maintenance ICS-LABA plus SABA 5.

Important nuance: The SMART regimen results in higher inhaled corticosteroid exposure (approximately 22% increase) but reduced oral corticosteroid exposure, with no significant difference in total systemic corticosteroid burden 4. This trade-off favors better asthma control with lower risk of systemic side effects.

Common Pitfalls to Avoid

  1. Do not prescribe separate inhalers - SMART requires a single combination inhaler for both maintenance and relief 3
  2. Only budesonide-formoterol and beclometasone-formoterol are validated for SMART - other ICS-LABA combinations have not been studied in this regimen 3
  3. Formoterol is essential - salmeterol does not provide rapid symptom relief and cannot be used for SMART 3
  4. Patient education is critical - provide a written asthma action plan explaining the dual role of the inhaler 3
  5. Mouth rinsing after each use reduces risk of oral candidiasis 2

Age-Specific Considerations

  • Ages ≥12 years: Full SMART regimen as described above 1, 3
  • Ages 6-11 years: Use budesonide-formoterol 80/4.5 mcg, 2 inhalations twice daily (maintenance only, not as reliever) 2
  • Ages 4-5 years: SMART has a strong recommendation but specific dosing requires careful titration 1

Timeline for Benefit

Symptom relief occurs within 15 minutes of administration, but maximum benefit requires 2 weeks or longer of consistent use 2. Reassess control at 1-2 weeks and adjust accordingly 2.

References

3
Research

A Practical Guide to Implementing SMART in Asthma Management.

The journal of allergy and clinical immunology. In practice, 2022

Related Questions

What is the SMART (Single Maintenance And Reliever Therapy) trial that supports using Symbicort (budesonide/formoterol) as both maintenance and reliever therapy in asthma?
What is the appropriate dosing regimen for a budesonide (200 µg)/formoterol (6 µg) combination inhaler in an adult with persistent asthma?
For a patient aged ≥6 years who is not adequately controlled on a lower‑dose inhaled corticosteroid, is Symbicort (budesonide/formoterol) dosed twice daily (BID)?
What is the recommended dosage of Symbicort (budesonide/formoterol) for asthma?
What are the dosing and administration instructions for Breztri (budesonide/formoterol) in a patient aged 12 years or older with persistent asthma?
What is the detailed receptor profile of escitalopram?
What is the appropriate workup for chest pain in primary care?
My AST is 22 U/L, ALT is 23 U/L, anti‑Jo‑1 antibody is <0.2 U, and I have a rheumatology appointment on Thursday; what further evaluation and management steps should I take for possible inflammatory myopathy?
What is the next best step in management for a 53-year-old female with chronic obstructive pulmonary disease and gout who presents with bilateral lower‑leg pain, medial foot numbness, and mild motor‑sensory neuropathy on nerve conduction studies?
In chronic idiopathic constipation or IBS‑C, how do Amitiza (lubiprostone) and Linzess (linaclotide) compare regarding dosing, contraindications, side‑effect profile, and patient suitability?
How can I switch a patient from immediate-release (IR) quetiapine 150 mg daily (75 mg twice daily) to the extended-release (QR) formulation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.